Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes
Asymptomatic hyperuricemia is common among patients with type 2 diabetes and has been associated with increased cardiovascular risk. However, evidence regarding the effects of empagliflozin on serum uric acid (SUA) and cardiovascular outcomes in this population remains limited. This study aimed to evaluate the impact o...